Online citations, reference lists, and bibliographies.
← Back to Search

A Survey Of The Syntheses Of Active Pharmaceutical Ingredients For Antiretroviral Drug Combinations Critical To Access In Emerging Nations.

E. Pinheiro, O. A. C. Antunes, J. Fortunak
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
It has been roughly 25 years since the threat posed by human immunodeficiency virus type 1 (HIV-1) became widely known. The cumulative death toll from HIV/AIDS is now greater than 25 million. There are approximately 33 million people living worldwide with this disease, of whom about 68% (22.5 million) live in sub-Saharan Africa (http://www.avert.org/worldstats.htm). A number of antiretroviral (ARV) drugs have been approved for treatment of HIV/AIDS. Inhibitors of HIV reverse transcriptase (RTIs) include the nucleoside/nucleotide drugs zidovudine, lamivudine, abacavir, didanosine, stavudine, emtricitabine and tenofovir disoproxil fumarate. Non-nucleoside RTIs include nevirapine, efavirenz and etravirine. Inhibitors of HIV protease (PIs) include saquinavir, ritonavir, lopinavir, nelfinavir, indinavir, fosamprenavir and atazanavir. Enfuvirtide inhibits the HIV fusion protein. The CCR5 chemokine antagonist maraviroc and the integrase inhibitor raltegravir were very recently approved by the US FDA. Fixed-dose combinations (FDCs) have been formulated to increase tolerability, convenience and compliance. First-line drug combinations are offered to treatment-naive patients, while second-line drugs are reserved for those who no longer respond adequately to first-line therapy. In developing countries a modest but increasing fraction of those infected have access to ARVs. The Clinton HIV/AIDS Initiative estimates that 2.4 million of the nearly 8 million individuals needing treatment in developing nations have access to some drugs. First-line FDCs used in resource-poor settings are largely combinations of two nucleoside RTIs and a non-nucleoside RTI or PI. The effectiveness of these combinations decreases over time, requiring a switch to combinations that retain potency in the presence of viral resistance. Increasing access to second-line FDCs and new developments in first-line ARV therapy are cost challenges. In high-income countries the cost of ARV therapy is largely irrelevant, except for "advanced salvage" drugs such as enfuvirtide. In resource-poor settings cost is a huge factor that limits drug access, resulting in high rates of new infection and subsequent mortality. IP coverage, where granted, can keep access prices for essential ARVs higher than would otherwise be the case. Large, innovator companies have made drugs available at prices very close to the cost of manufacturing for "lowest income" countries. Generic providers in India and elsewhere provide the largest supply of drugs for the developing world. The recent issuance of Voluntary and Compulsory Licenses (VLs, CLs) through the World Trade Organization's TRIP (Treaty Respecting Intellectual Property) provisions arguably contribute to bringing down access prices. The utilization of improved science, pooled purchasing and intelligent procurement practices all definitely contribute to access. This work surveys the production processes for several critical ARVs. These are discussed in terms of scale up, raw material/intermediates and active pharmaceutical ingredient (API) costs. In some cases new routes to APIs or critical intermediates are needed. Based on potential new chemistries, there are significant opportunities to reduce cost for a number of critical ARVs.
This paper references
10.2174/1568026043388358
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
G. Painter (2004)
10.1016/S0960-894X(99)00486-2
Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors
Mona Patel (1999)
10.1038/nrd2424
The design of drugs for HIV and HCV
E. Clercq (2007)
Retroviral protease inhibiting compounds
샴힝룽 (1996)
10.1021/JM00038A015
Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
J. Starrett (1994)
Process for the preparation of 5-hydroxymethylthiazole. US Patent 5,780,638
H. Kraus (1998)
10.1016/S0040-4020(02)01188-2
Recent applications of the Suzuki–Miyaura cross-coupling reaction in organic synthesis
S. Kotha (2002)
10.1016/J.TET.2004.06.028
Substrate-selective aqueous organometallic catalysis. How size and chemical modification of cyclodextrin influence the substrate selectivity
Christophe Torque (2004)
10.1002/CHIN.199545259
(2 + 3) Cycloadditions of Enantiomerically Pure Oxazoline-N-Oxides: A Short Stereoselective Synthesis of (+)-Carbovir.
T. Berranger (1995)
10.1248/CPB.50.1
Pd asymmetric allylic alkylation (AAA). A powerful synthetic tool.
B. Trost (2002)
Simplifying syntheses is always a key goal
A. M. Rouhi (2003)
10.1128/AAC.44.8.2093-2099.2000
BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents
B. S. Robinson (2000)
10.1021/OP025595S
In situ recycling of chiral ligand and surplus nucleophile for a noncatalytic reaction: Amplification of process throughput in the asymmetric addition step of efavirenz (DMP 266)
Anusuya Choudhury (2003)
10.1021/JA00047A024
Aza- and thiaarsolidinium cations: novel structural features for carbene analogues
N. Burford (1992)
10.1021/jo00057a011
Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic.
A. Ghosh (1993)
10.1016/0040-4039(95)01955-H
Use of an ephedrine alkoxide to mediate enantioselective addition of an acetylide to a prochiral ketone: asymmetric synthesis of the reverse transcriptase inhibitor L-743,726
A. S. Thompson (1995)
Intermediate for the preparation of peptide analogues
A. Fässler (1999)
10.1021/OP7001563
An Efficient and Practical Synthesis of the HIV Protease Inhibitor Atazanavir via a Highly Diastereoselective Reduction Approach
Xing Fan (2008)
Process for the preparation of arylpyridinyl compounds
C. Giordano (2001)
10.1002/CHIN.200731074
Miyaura—Suzuki Cross-Coupling Reactions: The Role of Pd/CaCO3 as Catalyst Reservoir.
B. L. Oliveira (2007)
10.1002/CHIN.199031059
Catalytic Asymmetric Synthesis of Optically Active Alkynyl Alcohols by Enantioselective Alkynylation of Aldehydes and by Enantioselective Alkylation of Alkynyl Aldehydes.
Seiji Niwa (1990)
5 - Fluorocytosine and preparation thereof
R. Duschinsky (1960)
10.1002/CHIN.200133036
Facile, Asymmetric Addition of Acetylene to Aldehydes: In situ Generation of Reactive Zinc Acetylide.
H. Sasaki (2010)
10.1023/B:PHAR.0000026815.44214.83
Increasing number of anti-HIV drugs but no definite cure Review of anti-HIV drugs
L. M. Stolk (2004)
Antiretroviral Therapy. American Society for Microbiology
E. De Clercq (2001)
10.1002/CHIN.200028074
A Novel, One‐Pot Ring Expansion of Cyclobutanones. Syntheses of Carbovir and Aristeromycin.
B. S. Brown (2000)
10.1016/J.TETLET.2003.09.018
Synthesis of a dicyclobutylideneethane derivative via sequential palladium-catalyzed Miyaura borylation and Suzuki coupling
G. Kabalka (2003)
10.1002/CHIN.200522159
Efficient Synthesis of Various Acycloalkenyl Derivatives of Pyrimidine Using Cross‐Metathesis and Pd(0) Methodologies.
F. Amblard (2005)
10.1021/JM00163A004
Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides.
R. Vince (1990)
10.1021/JA00439A046
Nucleic acid related compounds. 21. Direct fluorination of uracil and cytosine bases and nucleosides using trifluoromethyl hypofluorite. Mechanism, stereochemistry, and synthetic applications.
M. J. Robins (1976)
10.1128/AAC.36.11.2423
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
R. Schinazi (1992)
10.1016/S0040-4039(98)00131-2
Practical synthesis of the anti-HIV drug, PMPA
L. M. Schultze (1998)
10.1016/J.TETLET.2004.10.017
A stereoselective synthesis of silylated epoxycyclopentanols bearing four contiguous stereogenic centers
Serge Thorimbert (2004)
10.1016/S0040-4020(00)00422-1
Synthesis of Acyclic Nucleoside and Nucleotide Analogues from Amino Acids: A Convenient Approach to a PMEA–PMPA Hybrid
Arlen L Jeffery (2000)
5-Fluorocytosine and preparation thereof. US Patent 2,945,038
R. Duschinsky (1960)
10.1002/CHIN.199729231
Efficient Synthesis of Carbovir and Its Congener via π‐ Allylpalladium Complex Formation by Ring Strain‐Assisted C‐N Bond Cleavage.
N. Katagiri (1997)
10.1016/J.TETLET.2003.12.006
Synthesis of C1-alkyl- and acylglycals from glycals using a B-alkyl Suzuki-Miyaura cross coupling approach
J. Potuzak (2004)
10.1016/0960-894X(95)00515-4
Versatile synthetic routes to threo-β-amino hydroxy carboxylic acids, statine and its analogues
Sung Ho Kang (1995)
10.1016/0957-4166(95)00022-H
Enzymic resolution of oxathiolane intermediates — an alternative approach to the anti-viral agent lamivudine (3TC™)
R. P. Cousins (1995)
10.1021/JO00375A014
A short, stereoselective synthesis of the lactone precursor to 2R,4S,5S hydroxyethylene dipeptide isosteres
A. H. Fray (1986)
10.1002/CHIN.200147214
Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro‐Drug GS‐7340
H. H. Chapman (2001)
10.1021/JO00223A037
A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and .gamma.-(aminoalkyl)-.gamma.-lactones
B. Evans (1985)
10.1002/CHIN.199737225
A Convenient Synthesis of Enaminones Using Tandem Acetonitrile Condensation, Grignard Addition.
A. R. Haight (2010)
Facile inversion of configuration of N-BOC-betaaminoalcohols
F. Benedetti (2000)
10.2217/17460794.1.6.709
From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™
E. Clercq (2006)
10.1002/CHIN.200045170
Synthesis and Evaluation of Quinoxalinones as HIV-1 Reverse Transcriptase Inhibitors.
M. Patel (2000)
10.1021/OP980214P
Synthesis of ABT-378, an HIV Protease Inhibitor Candidate: Avoiding the Use of Carbodiimides in a Difficult Peptide Coupling
Eric J. Stoner (1999)
10.1021/JO025616G
Epoxyalcohol route to hydroxyethylene dipeptide isosteres. Stereodivergent synthesis of the diamino alcohol core of ritonavir and its C-2 epimer.
F. Benedetti (2002)
Process for preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues. WO9746515
A. Fässler (1997)
10.1128/AAC.37.2.332
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.
J. Balzarini (1993)
10.1016/S0040-4039(03)00749-4
Enantioselective synthesis of the carbocyclic moiety of (−)-carbovir
E. Roulland (2003)
10.1016/S0022-328X(03)00664-8
The silicon effect on the regioselectivity of the Tsuji-Trost reaction. Experimental and theoretical approaches
V. Branchadell (2003)
1,3-oxathiolane nucleoside analogues
알란 빅터 코우츠 조나단 (1991)
Biochemical and mechanistic
G. R. Painter (2004)
Benzoxazinones HIV reverse transcriptase inhibitors
S. D. Young (1995)
10.1016/S0022-328X(98)01088-2
Recent developments of palladium(0) catalyzed reactions in aqueous medium
J. Genêt (1999)
10.2174/1568026043388529
HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.
F. Rodríguez-Barrios (2004)
10.1128/AAC.37.11.2285
Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
L. Frick (1993)
1 , 3 - Oxathiolane nucleoside compounds and compositions
G. Dionne (1996)
Azahexane derivatives as substrate isosteres of retroviral aspartate proteases
A. Fässler (2001)
Process for the preparation of disubstituted carbonates
D. C. Langridge (1998)
5-Fluorouracil. US Patent 2,802,005
C. Heidelberger (1957)
10.1016/S0968-0896(00)82036-2
Design of orally bioavailable, symmetry-based inhibitors of HIV protease.
D. Kempf (1994)
A process for the preparation of 5-hydroxymethylthiazole
M. R. Leanna (1995)
10.1021/JM00166A019
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
C. U. Kim (1990)
10.1002/CHIN.200120161
Epoxyalcohol Route to Hydroxyethylene Dipeptide Isosteres: A New Synthesis of the Diaminoalcohol Core of HIV‐Protease Inhibitor ABT‐538 (Ritonavir).
F. Benedetti (2001)
Process for preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
A. Fässler (1997)
10.1021/AR990078O
The discovery of novel reactivity in the development of C-C bond-forming reactions: in situ generation of zinc acetylides with Zn(II)/R(3)N.
D. Frantz (2000)
10.1021/JO981170L
Practical asymmetric synthesis of Efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor
Michael E. Pierce (1998)
Process for the diastereoselective synthesis of nucleoside analogues
M. D. Goodyear (2000)
10.1021/JO9608230
Chemoenzymatic Synthesis of Antiviral Carbocyclic Nucleosides: Asymmetric Hydrolysis of meso-3,5-Bis(acetoxymethyl)cyclopentenes Using Rhizopusdelemar Lipase.
Masakazu Tanaka (1996)
10.1021/JO9707848
Synthesis of Biaryls via a Nickel(0)-Catalyzed Cross-Coupling Reaction of Chloroarenes with Arylboronic Acids.
S. Saito (1997)
10.1007/BF03264395
5-Fluorouracil
泰柄鎬 (1981)
10.1135/CCCC19951196
Synthesis of Enantiomeric N -(2-Phosphonomethoxypropyl) Derivatives of Purine and Pyrimidine Bases. II. The Synthon Approach
A. Holý (1995)
10.1016/S0040-4039(03)01081-5
A convenient preparation of dityrosine via Miyaura borylation–Suzuki coupling of iodotyrosine derivatives
C. Hutton (2003)
10.1002/CHIN.200120028
Highly Enantioselective Cyanosilylation of Aldehydes Catalyzed by a Lewis Acid-Lewis Base Bifunctional Catalyst.
Y. Hamashima (2001)
10.1021/jo00023a009
An Efficient Synthesis of Hydroxyethylene Dipeptide Isosteres: The Core Unit of Potent HIV-1 Protease Inhibitors.
A. Ghosh (1991)
10.1128/AAC.42.3.612
Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA
B. Robbins (1998)
10.1021/CEN-V081N044.P041
WHAT'S THAT STUFF?
R. Mullin (2003)
10.1128/AAC.42.7.1568
Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice
L. Naesens (1998)
10.1135/CCCC19823447
Preparation of 5'-O-phosphonylmethyl analogues of nucleoside-5'-phosphates, 5'-diphosphates and 5'-triphosphates
A. Holý (1982)
Antiviral drug discovery and development: where chemistry meets with biomedicine.
E. De Clercq (2005)
Process for thepreparationof 5 - hydroxymethylthiazoles
M. S. Allen (1999)
Process for preparation of 5-hydroxymethylthiazole. World Patent WO9616050A1
M. R. Leanna (1996)
10.1016/S0040-4039(00)01923-7
Enantioselective Strecker-type reaction promoted by polymer-supported bifunctional catalyst
Hiroyuki Nogami (2001)
10.1016/S0166-3542(98)00025-4
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
E. Clercq (1998)
Synthesis and anti-HIV activity of carbocyclic
R. Vince (1990)
10.1021/OP025504R
Process Research and Development for an Efficient Synthesis of the HIV Protease Inhibitor BMS-232632
Z. Xu (2002)
10.1021/OL0524104
Stereoselective hydroazidation of amino enones: synthesis of the ritonavir/lopinavir core.
I. Adamo (2006)
10.1002/CHIN.199822156
Practical Enantiodivergent Syntheses of Both Enantiomers of Carbovir, 1592U89 and Six‐Membered Ring Analogues.
H. Olivo (1998)
10.1128/AAC.44.9.2319-2326.2000
In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632
Y. F. Gong (2000)
Process for preparation of 5hydroxymethylthiazole. US Patent 5,712,400
M. R. Leanna (1998)
10.1002/CHIN.200431028
BINOL—Salen‐Catalyzed Highly Enantioselective Alkyne Additions to Aromatic Aldehydes.
Zi-Bo Li (2004)
10.1002/CHIN.199930031
A New Bifunctional Asymmetric Catalysis: An Efficient Catalytic Asymmetric Cyanosilylation of Aldehydes.
Y. Hamashima (1999)
10.1016/J.TETLET.2004.06.127
Alkoxy group facilitated ring closing metathesis (RCM) of acyclic 1,6-dienes. Convenient synthesis of non-racemic highly substituted cyclopentenols
Abhijit Nayek (2004)
10.5860/choice.29-5704
The chemical synthesis of peptides
J. Jones (1991)
10.1021/IE030225T
Separation of FTC-ester enantiomers using a simulated moving bed
Yi Xie (2003)
1,3Oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
K.S.K. Murth (2002)
Peptides : synthesis, structures, and applications
B. Gutte (1995)
10.1002/CHIN.200418125
The Preparation of a Stable 2-Pyridylboronate and Its Reactivity in the Suzuki—Miyaura Cross-Coupling Reaction.
P. Hodgson (2004)
10.1002/CHIN.199252109
Palladium‐Catalyzed Cross‐Coupling Reactions of Arylboronic Acids with π‐Deficient Heteroaryl Chlorides.
N. M. Ali (1992)
Stereoselective hydroazidation
I. Adamo (2006)
Therapeutic nucleosides. US Patent 5,034,394
S. M. Daluge (1991)
Process for the preparation of thiazole derivatives
토마스 핏터나 (1997)
10.1021/JA00048A083
A novel palladium-catalyzed cycloalkylation to isoxazoline 2-oxides. Application for the asymmetric synthesis of carbanucleosides.
B. Trost (1992)
10.1016/S0040-4020(98)00320-2
New developments in the enantioselective synthesis of cyclopentyl carbocyclic nucleosides
M. T. Crimmins (1998)
10.1126/science.270.5239.1197
Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine
C. Tsai (1995)
10.1002/CHIN.200046026
Allylic Alcohols via Catalytic Asymmetric Epoxide Rearrangement.
M. Södergren (2000)
10.1016/S0166-3542(98)00041-2
Recent advances in L-nucleosides: chemistry and biology.
P. Wang (1998)
10.1056/NEJM199804303381808
HIV-protease inhibitors.
C. Flexner (1998)
10.1021/OP980067V
Process Optimization in the Synthesis of 9-[2-(Diethylphosphonomethoxy)ethyl]adenine: Replacement of Sodium Hydride with Sodium tert-Butoxide as the Base for Oxygen Alkylation
R. C. Yu (1999)
10.1016/S0040-4039(02)02793-4
2-(Fluorophenyl)pyridines by the Suzuki–Miyaura method: Ag2O accelerates coupling over undesired ipso substitution (SNAr) of fluorine
J. Chen (2003)
10.1016/0968-0896(94)80005-7
Enzyme-catalysed kinetic resolution of 4-endo-hydroxy-2-oxabicyclo[3.3.0]oct-7-en-3-one and employment of the pure enantiomers for the synthesis of anti-viral and hypocholestemic agents.
R. Mackeith (1994)
10.1021/CR040673Q
α-aminoalkyl-α'-halomethylketones : Preparation and application to pharmaceutically interesting compounds
M. R. Reeder (2006)
10.1039/P19940003373
Concise racemic and highly enantioselective approaches to key intermediates for the syntheses of carbocyclic nucleosides and pseudo-ribofuranoses: formal syntheses of carbovir
D. Hodgson (1994)
Process for the diastereoselective synthesis of nucleoside analogues. WO9529174
M. D. Goodyear (1995)
10.1002/CHIN.200441092
Diastereoselective Zinc‐Catalyzed Conjugate Addition of Alkynes.
T. Knöpfel (2004)
10.1002/CHIN.199851232
New Aza‐Dipeptide Analogues as Potent and Orally Absorbed HIV‐1 Protease Inhibitors: Candidates for Clinical Development.
G. Bold (1998)
10.1016/s0008-6215(00)00089-6
Fluorinated nucleosides.
K. Pankiewicz (2000)
10.1021/OL062715Y
Directed reductive amination of beta-hydroxy-ketones: convergent assembly of the ritonavir/lopinavir core.
D. Menche (2007)
10.1007/BF01569915
Stereospecificγ-lactamase activity in aPseudomonas fluorescens species
A. Brabban (2005)
10.1021/JA993838Z
Facile Enantioselective Synthesis of Propargylic Alcohols by Direct Addition of Terminal Alkynes to Aldehydes
D. Frantz (2000)
10.1006/BBRC.1996.0234
Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems.
J. Balzarini (1996)
10.1021/CR00104A001
Directed ortho metalation. Tertiary amide and O-carbamate directors in synthetic strategies for polysubstituted aromatics
V. Snieckus (1990)
10.1021/CR050997U
Industrial syntheses of the central core molecules of HIV protease inhibitors.
K. Izawa (2006)
10.1177/095632029700800610
Synthesis, in Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)Propyl]Adenine (PMPA) Prodrugs
M. Arimilli (1997)
10.1016/J.TET.2003.10.116
Use of hydrolases for the synthesis of cyclic amino acids
R. C. Lloyd (2004)
10.1002/CHIN.200117211
An Efficient, General Asymmetric Synthesis of Carbocyclic Nucleosides: Application of an Asymmetric Aldol/Ring‐Closing Metathesis Strategy.
M. T. Crimmins (2001)
Inibidores da HIV-1 Protease: Uma Revisão
O.A.C. Antunes (1996)
10.1248/CPB.51.702
Application of the Lewis acid-Lewis base bifunctional asymmetric catalysts to pharmaceutical syntheses: stereoselective chiral building block syntheses of human immunodeficiency virus (HIV) protease inhibitor and beta3-adenergic receptor agonist.
Hiroyuki Nogami (2003)
10.1021/JO9823893
Acylnitrene Route to Vicinal Amino Alcohols. Application to the Synthesis of (-)-Bestatin and Analogues.
S. Bergmeier (1999)
10.1016/S0040-4039(00)01753-6
Facile inversion of configuration of N-Boc-β-aminoalcohols via SN2 cyclization to oxazolidinones
F. Benedetti (2000)
Nucleic acid related compounds
M. J. Robins (1976)
10.1345/aph.1C388
Tenofovir Disoproxil Fumarate
S. Grim (2003)
10.1021/OP0500180
Cost Estimates for New Molecules
T. Laird (2005)
10.1073/PNAS.92.7.2484
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
D. Kempf (1995)
10.1039/P19920000589
Potential use of carbocyclic nucleosides for the treatment of AIDS: chemo-enzymatic syntheses of the enantiomers of carbovir
C. T. Evans (1992)
10.1021/JM960289O
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
S. Benzaria (1996)
Process for the production of 2 - azabicyclo [ 2 . 2 . 1 ] hep - 5 - ene - 3 - one
G. Griffiths (1993)
10.1021/JO00384A020
A synthesis of protected aminoalkyl epoxides from .alpha.-amino acids
J. Luly (1987)
10.1016/S0040-4020(01)80481-6
Palladium-catalysed cross-coupling reactions of arylboronic acids with π-deficient heteroaryl chlorides
N. M. Ali (1992)
Process for preparing alcohol by heterocyclic carboxylic ester reduction
靳立人 (2003)
10.1517/13543784.13.1.55
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy
P. Cahn (2004)
10.1038/nrd1877
Acyclic nucleoside phosphonates: a key class of antiviral drugs
E. Clercq (2005)
10.1016/J.TETLET.2003.09.038
Water-mediated transition-metal-free Tsuji–Trost-type reaction
Carole Chevrin (2003)
10.1002/CHIN.199632128
A Synthesis of Biaryls via Nickel(0)-Catalyzed Cross-Coupling Reaction of Chloroarenes with Phenylboronic Acids.
S. Saito (2010)
Process for the production of 2-azabicyclo[2.2.1]hep5-ene-3-one. US Patent 5,200,527
G. Griffiths (1993)
Pharmaceutical Substances: Book and CD-ROM
A. Kleemann (1999)
10.1002/(SICI)1099-0690(199906)1999:6<1455::AID-EJOC1455>3.0.CO;2-V
A New Strategy for the Asymmetric Synthesis of 1,3-Oxathiolane-Based Nucleoside Analogues
R. Caputo (1999)
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
M. N. Arimilli (1999)
10.1002/CHIN.200352095
Palladium-Catalyzed Suzuki—Miyaura Reaction Using Aminophosphine as Ligand.
J. Cheng (2003)
10.1002/CHIN.200111032
Facile Inversion of Configuration of N‐Boc‐β‐aminoalcohols via SN2 Cyclization to Oxazolidinones.
F. Benedetti (2001)
10.1002/CHIN.199929027
A Novel, Highly Enantioselective Ketone Alkynylation Reaction Mediated by Chiral Zinc Aminoalkoxides.
L. Tan (1999)
Therapeutic nucleosides
S. M. Daluge
10.1002/CHIN.199938182
Asymmetric Dihydroxylation Route to a Dipeptide Isostere of a Protease Inhibitor: Enantioselective Synthesis of the Core Unit of Ritonavir.
A. Ghosh (1999)
10.1146/ANNUREV.BIOPHYS.27.1.249
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
A. Wlodawer (1998)
10.1590/S0100-40422002000700012
Estratégias farmacológicas para a terapia anti-AIDS
E. P. Peçanha (2002)
10.1016/J.TET.2004.07.009
Synthesis of l-cyclopentenyl nucleosides using ring-closing metathesis and palladium-mediated allylic alkylation methodologies
L. Agrofoglio (2004)
10.1021/JO962416U
Efficient Synthesis of Carbovir and Its Congener via π-Allylpalladium Complex Formation by Ring Strain-Assisted C−N Bond Cleavage
N. Katagiri (1997)
10.1016/0040-4039(95)01380-Z
ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF THE ANTI-VIRAL AGENT LAMIVUDINE (3TC)
J. Milton (1995)
10.1002/CHIN.199601266
Synthesis of Enantiomeric N-(2-Phosphonomethoxypropyl) Derivatives of Purine and Pyrimidine Bases. Part 1. The Stepwise Approach.
A. Holý (1996)
10.1002/CHIN.199905090
Transition-State Mimetics for HIV Protease Inhibitors: Stereocontrolled Synthesis of Hydroxyethylene and Hydroxyethylamine Isosteres by Ester-Derived Titanium Enolate syn and anti-Aldol Reactions.
A. Ghosh (1999)
10.1002/CHIN.199827150
Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy.
D. Kempf (1998)
Process for the preparation of disubstituted carbonates. US Patent 5,773,625
D. C. Langridge (1998)
10.1345/aph.1A363
Kaletra (Lopinavir/Ritonavir)
A. Corbett (2002)
10.1002/CHIN.199504237
An Efficient Stereocontrolled Strategy for the Synthesis of Hydroxyethylene Dipeptide Isosteres.
T. L. Stuk (1995)
10.1016/S0960-894X(99)00565-X
Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVATM)
Mona Patel (1999)
10.1016/S0960-894X(01)00243-8
Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).
H. Sham (2001)
10.1021/OP9802071
Reduction of an Enaminone: Synthesis of the Diamino Alcohol Core of Ritonavir
A. R. Haight (1999)
1,3-Oxathiolane nucleoside compounds and compositions. US Patent 5,538,975
G. Dionne (1996)
10.1021/JA9713791
Lithium Ephedrate-Mediated Addition of a Lithium Acetylide to a Ketone: Solution Structures and Relative Reactivities of Mixed Aggregates Underlying the High Enantioselectivities
A. Thompson (1998)
10.1016/S0040-4039(98)00897-1
A concise synthesis of aza-dipeptide isosteres
A. Faessler (1998)
10.1080/00397919708005064
Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266
L. Radesca (1997)
10.1016/0957-4166(94)80072-3
An asymmetric synthesis of (−)-carbovir
Masatoshi Asami (1994)
10.1021/CR000446Y
Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides, and C-nucleosides.
M. Ferrero (2000)
10.2174/157017807780037540
Miyaura-Suzuki Cross Coupling Reactions: The Role of Pd/CaCO3 as Catalyst Reservoir
Bianca L. Oliveira and Octavio A. C. Antunes (2007)
10.1021/JO960708P
An Efficient Asymmetric Approach to Carbocyclic Nucleosides: Asymmetric Synthesis of 1592U89, a Potent Inhibitor of HIV Reverse Transcriptase.
M. T. Crimmins (1996)



This paper is referenced by
10.1186/1744-8603-6-9
Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets
B. Waning (2010)
Efetividade dos esquemas antirretrovirais de primeira e segunda linha utilizados no tratamento de Pacientes com HIV/AIDS numa coorte urbana no Rio de Janeiro
Sandra Cardoso (2014)
10.1007/s40121-018-0194-1
Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals
J. LaFleur (2018)
10.1002/ANGE.201201636
Industrielle Anwendungen der Diels‐Alder‐Reaktion
Jacques-Alexis Funel (2013)
10.2217/HIV.09.35
Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.
C. Wester (2009)
A catch-22? : an exploration of the domestic production of antiretroviral drugs in Uganda
M. E. Warren (2012)
10.1002/9781118498088.CH16
Stereoselective Methods in the Synthesis of Bioactive Oxathiolane and Dioxolane Nucleosides
Daniele D'Alonzo (2013)
10.1039/c3ob41464g
A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir.
Luciana Dalla-Vechia (2013)
10.1002/anie.201201636
Industrial applications of the Diels-Alder reaction.
Jacques-Alexis Funel (2013)
10.15406/JHVRV.2015.02.00034
Chronic Immune Activation is the Cause of AIDS: Implication of Treatment in the Developing World
Olga N. Malykhina (2015)
10.1007/s11095-010-0077-y
Release of Plasmid DNA-Encoding IL-10 from PLGA Microparticles Facilitates Long-Term Reversal of Neuropathic Pain Following a Single Intrathecal Administration
R. Soderquist (2010)
10.1016/j.jpba.2010.07.022
Micellar electrokinetic chromatography method development for determination of impurities in ritonavir.
A. Z. Carvalho (2010)
DEVELOPMENT AND VALIDATION OF A METHOD FOR THE ASSAY AND DISSOLUTION OF A FIXED DOSE COMBINATION OF LAMIVUDINE, TENOFOVIR AND EFAVIRENZ TABLET
Bwiro Joseph (2011)
10.1016/J.TET.2018.12.014
Base catalyzed unexpected rearrangement of isatin-derived N,N′-cyclic azomethine imines and Michael addition to hindered vinylidene bisphosphonates: Access to 3,3-disubstituted oxindole-fused pyrazolidin-3-one derivatives containing bisphosphonates
Qinghe Wang (2019)
10.1038/nature16440
Network Analysis Guided Synthesis of Weisaconitine D and Liljestrandinine
C. J. Marth (2015)
10.3851/IMP2900
Production of antiretroviral drugs in middle- and low-income countries.
E. Pinheiro (2014)
10.1016/J.CEP.2015.07.018
Evaluating the potential for the continuous processing of pharmaceutical products - a supply network perspective
J. Srai (2015)
10.14288/1.0072871
Therapy-related hepatic mitochondrial dysfunction in patients co-infected with human immunodeficiency virus and hepatitis C virus and in HepG2 cells
Rachel Taillefer (2012)
10.1107/S1744309111010414
Molecular cloning, overexpression, purification, crystallization and preliminary X-ray diffraction analysis of a purine nucleoside phosphorylase from Bacillus subtilis strain 168.
N. H. Martins (2011)
10.1007/978-3-319-76834-2_3
Nationalizing Efavirenz: Compulsory Licence, Collective Invention and Neo-Developmentalism in Brazil
M. Cassier (2019)
10.1097/QAI.0000000000001608
Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans Risk Modification by Concomitant Antiretrovirals
J. LaFleur (2018)
10.1016/j.saa.2015.12.008
A combined TD-DFT and spectroscopic investigation of the solute-solvent interactions of efavirenz.
M. A. Jordaan (2016)
10.3917/AUTR.063.0107
Nationaliser l'efavirenz : licence obligatoire, invention collective et néo-développementisme au Brésil (2001-2012)
M. Cassier (2012)
10.2174/1874613601004020070
Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics
Daniele Dionisio (2010)
10.1021/acs.orglett.5b00982
Highly Stereoselective Synthesis of Lamivudine (3TC) and Emtricitabine (FTC) by a Novel N-Glycosidation Procedure.
Maria Federica Caso (2015)
10.1371/journal.pone.0164619
Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025
A. Gupta (2016)
10.1097/COH.0b013e328333ad45
Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options
A. De Luca (2010)
10.1039/c5cc04445f
Enantio- and diastereoselective synthesis of γ-amino alcohols.
J. M. M. Verkade (2015)
10.1002/9780470711828.CH26
Green Chemistry for Tropical Diseases
J. Fortunak (2012)
10.1007/s10593-013-1206-4
Stereoselective synthesis of 1-methyl-1,2-and 1,3-cyclopentanediols via γ-lactones
A. Niidu (2013)
Semantic Scholar Logo Some data provided by SemanticScholar